Company intelligence / Profile preview

Nexo Therapeutics

Littleton, Colorado, United Statesnexotx.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

Nexo Therapeutics has emerged from stealth with a $60 million Series A financing to advance its proprietary platforms for discovering small molecule therapies against previously undruggable cancer targets. The company has not yet reported clinical results; all programs are believed to be preclinical as of the latest updates.

Therapeutic areas: OncologyRare Diseases
Modalities: Small moleculesCovalent ligandsChimeric proteins (for target validation)
Industry: Biotech

Partnerships

University of Texas MD Anderson Cancer Center – multi-year strategic collaboration to accelerate development and translation of new small-molecule oncology therapies from discovery through IND-enabling studies.

Beyond the preview

Go deeper on Nexo Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nexo Therapeutics.

Explore the full profile